fda gilead - Search News

News

FDA Approves HIV Shot That’s 99.9% Effective

FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price.

ConsumerAffairs · 4h

FDA approves twice-yearly injection for HIV prevention

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect Efficacy With 99.9% of Pa

CNBC on MSN · 1d

FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option

The launch of the injection faces potential threats, including the Trump administration's proposed cuts to federal funding for HIV prevention efforts.

FDA Approves First Twice-a-Year HIV Prevention Shot

FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be ...

Pharmalittle: We’re reading about FDA forcing out top gene therapy regulator, Gilead’s HIV challenges and more

And more pharma news updates from Pharmalittle.

2d

Should You Buy Gilead Stock At $110?

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

Fierce Pharma1d

FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results